TandemHeart Experiences and MEthods (THEME Registry)

Study Overview
=================
Brief Summary
-----------------
This study is intended to be a multicenter, prospective observation registry. By collecting prospective descriptive data, provide insight into disease defining characteristics resulting in the clinical decision to use TandemHeart® or LifeSPARC™ System for mechanical support and enhance knowledge of best practice regarding clinical management, weaning and removal/exit strategies.

Detailed Description
-----------------
The TandemHeart or LifeSPARC percutaneous extracorporeal life support system is used to support circulation. The percutaneous cannulas facilitate access to the venous and arterial circulatory vessels. When connected to the TandemHeart or LifeSPARC centrifugal pump, mechanical support is provided with sufficient cardiac power to perfuse the organs of the body. It is anticipated that THEME Registry™ analysis will provide insight into disease defining characteristics resulting in the clinical decision to use the TandemHeart or LifeSPARC System for mechanical support and enhance knowledge of best practice regarding clinical management, weaning and removal. The progression of the illness prior to, during and following support will be collected. The THEME Registry will collect descriptive data regarding patient selection criteria and the clinical management of the patient including strategies used to wean and remove the device. Specifically the objectives of the THEME Registry are: Summarize the characteristics of the patients who receive the System for temporary percutaneous mechanical support with or without an oxygenator, including demographics, pre-implant medical history, details of present illness, exit strategy. Evaluate the timing of initiation of System support in relation to the progression of the presenting illness and the association of this with clinical outcomes. Collect descriptive data related to clinical management of the patient while on mechanical support, including procedural details, duration of support, anticoagulation, hemodynamics and biochemical parameters to define trends in clinical care and the association of this decision-making with clinical outcomes. Collect hospital discharge information including Intensive Care Unit (ICU) and Hospital length of stay (LOS). Collect survival and exit strategy status at 30 and 180 days post-initial System insertion. Collect serious adverse events from the time of Pump insertion through removal of the System (or Pump). Provide data regarding patient characteristics and outcomes.

Official Title
-----------------
THEME Registry: TandemHeart Experiences and MEthods (THEME Registry)

Conditions
-----------------
Heart Diseases, Lung Diseases

Intervention / Treatment
-----------------
* Device: TandemHeart or LifeSPARC System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has had the TandemHeart or LifeSPARC System inserted percutaneously (e.g. in the cath lab or peri-operatively) Age >= 18 Patient (or legally authorized representative [LAR]) has signed informed consent Exclusion Criteria: Patient is incarcerated (prisoner) Participation in a clinical trial of an investigational drug or device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: TandemHeart or LifeSPARC System|Percutaneous insertion of TandemHeart or LifeSPARC System|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival to Pump removal with myocardial and/or pulmonary recovery, durable ventricular assist device (VAD) implant or transition to another mechanical support device, or cardiac and/or lung transplant | Survival | 180 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of Serious Adverse Events (SAEs) related to the device while on support | Serious Adverse Events | Approximately 72 hours after start of support | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Circulatory support, Extracorporeal circulatory support, Extracorporeal bypass, LifeSPARC